Acquisition extends OraSure’s leadership position in the microbiome services industry BETHLEHEM, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of Diversigen in an all-cash transaction. Diversigen…
“The virome is comprised of endogenous retroviruses, eukaryotic viruses, and bacteriophages and is increasingly being recognized as an essential part of the human microbiome. The human virome is associated with Type-1 diabetes (T1D), Type-2 diabetes (T2D), Inflammatory Bowel Disease (IBD), Human Immunodeficiency Virus (HIV) infection, and cancer. Increasing evidence also supports trans-kingdom interactions of viruses…
“Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels.” Read More
Nature Communications publishes new research from Joseph Petrosino, PhD, Diversigen Founder and Chief Science Officer, and other leading researchers. Using multidisciplinary approaches, the research report shows that a complex interplay between human milk oligosaccharid[es (HMOs), milk microbiome, and infant gut microbiome impacts neonatal rotavirus infections.
Diversigen will serve as a central lab for the generation of high quality microbiome data to be incorporated into the Crohn’s & Colitis Foundation’s IBD Plexus® platform.
Topping the 11th annual list is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.
Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability
4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).
Diversigen Announces Strategic Partnership with Korea-based BioCore Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with BioCore Co. Ltd., a leading bioanalytical contract research organization, based in Seoul, South Korea.